Abstract for MM-1 working group

MM-1 working group was established for generating clinical data from Taiwan perspective.  We are currently running three programs.  The first program is focusing on optimal dose of thalidomide in VTD regimen for NDMM.  Our results showed around 50% of NDMM patients were able to receive thalidomide 100mg per day.  The major reason for not able to receive thalidomide 100mg per day was constipation.  The second program was focusing on cytogenetics abnormalities in RRMM after Velcade-based regimen.  Only about 10% of these patients harbored high risk cytogenetic feature.  The third program was focusing on real-world data of pomalidomide and dexamethasone treatment in RRMM.  The median progression free survival was around 9 months in our study cohort.